Alonso-Arias, R. (R.)

Filtering

20101

Settings

Author search.filters.isAuthorOfPublication.77ddabbd-758b-40d8-9ef5-c5da65652bd4

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection
    (American Society for Microbiology, 2010) Vidal-Castiñeira, J.R. (Juan Ramón); Melon, S. (S.); Rodrigo, L. (Luis); Diaz-Peña, R. (R.); Perez, R. (R.); Lopez-Larrea, C. (Carlos); Lopez-Vazquez, A. (Antonio); Prieto, J. (Jesús); Fernandez-Suarez, J. (J.); Martinez-Borra, J. (Jesús); Alonso-Arias, R. (R.)
    Killer immunoglobulin-like receptors (KIRs) are related to the activation and inhibition of NK cells and may play an important role in the innate response against infection with viruses such as hepatitis C virus (HCV). We examined whether the different combinations of KIRs with their HLA class I ligands influenced the response to combined treatment (pegylated alpha interferon and ribavirin) of patients infected by HCV. A total of 186 consecutive patients diagnosed with chronic HCV infection were analyzed. Seventy-seven patients exhibited HCV RNA levels at 6 months posttreatment and were called nonresponders (NR), while 109 cleared viral RNA and were named sustained viral responders (SVR). Patients were typed for HLA-B, HLA-Cw, KIR genes, and HCV genotype. In our study, the frequency of the KIR2DL2 allele was significantly increased in NR (P < 0.001; odds ratio [OR] = 1.95), as was the frequency of the KIR2DL2/KIR2DL2 genotype (P < 0.005; OR = 2.52). In contrast, the frequencies of the KIR2DL3 genotype (P < 0.001) and KIR2DL3/KIR2DL3 genotype (P < 0.05; OR = 0.54) were significantly increased in the SVR. Different combinations of KIR2DL2 and KIR2DL3 alleles with their ligands were analyzed. The frequency of the KIR2DL2/KIR2DL2-HLA-C1C2 genotype was significantly increased in the NR (P < 0.01; OR = 3.15). Additionally, we found a higher frequency of the KIR2DL3/KIR2DL3-HLA-C1C1 genotype in the SVR group (P < 0.05; OR = 0.33). These results were not affected by the HCV genotype. In conclusion, patients who carried the KIR2DL2/KIR2DL2-HLA-C1C2 genotype were less prone to respond to treatment. However, the KIR2DL3/KIR2DL3-HLA-C1C1 genotype clearly correlated with a satisfactory response to treatment, defined by the clearance of HCV RNA.